Vicapsys Life Sciences, Inc.
VICP
$1.77
$0.5039.37%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 13.30% | 28.50% | 1.29% | 245.93% | 21.27% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.40% | 33.97% | -3.31% | 245.93% | 20.88% |
| Operating Income | -13.40% | -33.97% | 3.31% | -245.93% | -20.88% |
| Income Before Tax | 2.00% | -40.09% | -54.80% | -20.75% | -65.61% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 2.00% | -40.09% | -54.80% | -20.75% | -65.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2.00% | -40.09% | -54.80% | -20.75% | -65.61% |
| EBIT | -13.40% | -33.97% | 3.31% | -245.93% | -20.88% |
| EBITDA | -- | -- | -- | -259.20% | -22.07% |
| EPS Basic | 1.43% | -47.37% | -67.21% | -7.59% | -45.83% |
| Normalized Basic EPS | 2.27% | -45.83% | -23.68% | -241.94% | -51.72% |
| EPS Diluted | 1.43% | -47.37% | -67.21% | -7.59% | -45.83% |
| Normalized Diluted EPS | 2.27% | -45.83% | -23.68% | -241.94% | -51.72% |
| Average Basic Shares Outstanding | -0.23% | -3.19% | -7.27% | 12.13% | 10.31% |
| Average Diluted Shares Outstanding | -0.23% | -3.19% | -7.27% | 12.13% | 10.31% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |